Drugs / Suxiao Jiuxin Pills
Suxiao Jiuxin Pills
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05466968 | Aug 2022 → Jun 2025 overdue | acute myocardial infarction | Xiaolu Li | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04814121 | May 2021 → Sep 2023 | acute coronary syndrome | Guangzhou University of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suxiao Jiuxin Pills | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04814121 ↗ |
| Known as | Suxiao Jiuxin Pill | “Suxiao Jiuxin Pill is a classic old medicine, but large-scale randomized controlled trial are still needed to consolidate the efficacy, safety and modern scientific basis in...” NCT05466968 ↗ |
| Known as | SXJX | “Suxiao Jiuxin Pills (SXJX) was shown associated with a reduction in MACE, and an improvement of heart function and quality of life in acute coronary syndrome (ACS) patients...” NCT04814121 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “traditional Chinese medicine” NCT05466968 ↗ |